Human ribonucleotide reductase M2 subunit
OwnerYun Yeninventor
Life of this patent
Estimating the term…
Abstract
An isolated nucleic acid containing a human ribonucleotide reductase M2 subunit promoter sequence or genomic sequence. Also disclosed are methods of determining whether a subject is suffering from or at risk for developing a cell proliferation-associated disorder, identifying a compound for treating a cell proliferation-associated disorder, treating a cell proliferation-associated disorder, and developing a procedure for treating a cell proliferation-associated disorder.
Claims50
An isolated nucleic acid comprising:
- a promoter sequence at least 60% identical to SEQ ID NO:
- 2, and
- a nucleotide sequence encoding a transcript,
- wherein the promoter sequence is operably linked to the nucleotide sequence.
An isolated nucleic acid comprising:
- a promoter sequence at least 60% identical to SEQ ID NO:
- 3, and
- a nucleotide sequence encoding a transcript,
- wherein the promoter sequence is operably linked to the nucleotide sequence.
An isolated nucleic acid comprising:
- a promoter sequence at least 80% identical to SEQ ID NO:
- 4, and
- a nucleotide sequence encoding a transcript,
- wherein the promoter sequence is operably linked to the nucleotide sequence.
An isolated nucleic acid at least 86% identical to SEQ ID NO:
- 1.
A method of determining whether a subject is suffering from or at risk for developing a cell proliferation-associated disorder, the method comprising:
- providing a test sample containing genomic DNA from a subject, and
- determining a level of RRM2 genomic DNA in the test sample,
- wherein the level of RRM2 genomic DNA in the test sample, if higher than that in a normal sample, indicates that the subject is suffering from or at risk for developing a cell proliferation-associated disorder.
A method of identifying a compound for treating a cell proliferation-associated disorder, the method comprising:
- contacting a compound with a cell containing amplified RRM2 genomic DNA, and
- determining a level of RRM2 genomic DNA,
- wherein the level of RRM2 genomic DNA in the presence of the compound, if lower than that in the absence of the compound, indicates that the compound is a candidate for treating a cell proliferation-associated disorder.
A method of identifying a compound for treating a cell proliferation-associated disorder, the method comprising:
- contacting a compound with a system containing a nucleic acid that includes a marker nucleotide sequence operably linked to a promoter sequence of SEQ ID NO:
- 2, 3, or 4, and
- determining an expression level of the marker nucleotide sequence,
- wherein the expression level of the marker nucleotide sequence in the presence of the compound, if different from that in the absence of the compound, indicates that the compound is a candidate for treating a cell proliferation-associated disorder.
A method of identifying a compound for treating a cell proliferation-associated disorder, the method comprising:
- contacting a compound with a cell containing amplified RRM2 genomic DNA and expressing RRM1, and
- determining a level of RRM1 mRNA or protein in the cell,
- wherein the level of RRM1 mRNA or protein in the presence of the compound, if lower than that in the absence of the compound, indicates that the compound is a candidate for treating a cell proliferation-associated disorder.
A method of identifying a compound for treating a cell proliferation-associated disorder, the method comprising:
- contacting a compound with a cell containing amplified RRM2 genomic DNA and expressing p53R2, and
- determining a level of p53R2 mRNA or protein in the cell,
- wherein the level of p53R2 mRNA or protein in the presence of the compound, if lower than that in the absence of the compound, indicates that the compound is a candidate for treating a cell proliferation-associated disorder.
A method of identifying a compound for treating a cell proliferation-associated disorder, the method comprising:
- contacting a compound with a cell containing amplified RRM2 genomic DNA and expressing RRM1, and
- determining a level of RRM1 and RRM2 interaction in the cell,
- wherein the level of RRM1 and RRM2 interaction in the presence of the compound, if lower than that in the absence of the compound, indicates that the compound is a candidate for treating a cell proliferation-associated disorder.
A method of identifying a compound for treating a cell proliferation-associated disorder, the method comprising:
- contacting a compound with a cell containing amplified RRM2 genomic DNA and expressing RRM1 and p53R2, and
- determining a level of RRM1 and p53R2 interaction in the cell,
- wherein the level of RRM1 and p53R2 interaction in the presence of the compound, if lower than that in the absence of the compound, indicates that the compound is a candidate for treating a cell proliferation-associated disorder.
A method of treating a cell proliferation-associated disorder, the method comprising:
- identifying a subject whose RRM2 genomic DNA is amplified, and
- administering to the subject an effective amount of a compound that reduces a level of RRM2 genomic DNA in the subject.
A method of treating a cell proliferation-associated disorder, the method comprising:
- identifying a subject whose RRM2 genomic DNA is amplified, and
- administering to the subject an effective amount of a compound that reduces transcription from a promoter sequence of SEQ ID NO:
- 2, 3, or 4 in the subject.
A method of treating a cell proliferation-associated disorder, the method comprising:
- identifying a subject whose RRM2 genomic DNA is amplified, and
- administering to the subject an effective amount of a compound that reduces a level of RRM1 mRNA or protein in the subject.
A method of treating a cell proliferation-associated disorder, the method comprising:
- identifying a subject whose RRM2 genomic DNA is amplified, and
- administering to the subject an effective amount of a compound that reduces a level of RRM2 mRNA or protein in the subject.
A method of treating a cell proliferation-associated disorder, the method comprising:
- identifying a subject whose RRM2 genomic DNA is amplified, and
- administering to the subject an effective amount of a compound that reduces a level of p53R2 mRNA or protein in the subject.
A method of treating a cell proliferation-associated disorder, the method comprising:
- identifying a subject whose RRM2 genomic DNA is amplified, and
- administering to the subject an effective amount of a compound that reduces RRM1 and RRM2 interaction in the subject.
A method of treating a cell proliferation-associated disorder, the method comprising:
- identifying a subject whose RRM2 genomic DNA is amplified, and
- administering to the subject an effective amount of a compound that reduces RRM1 and p53R2 interaction in the subject.
A method of treating a cell proliferation-associated disorder, the method comprising:
- identifying a subject whose RRM2 genomic DNA is amplified, and
- administering to the subject an effective amount of an RRM2 inhibitor followed by administering to the subject an effective amount of a nucleotide or nucleoside analog.
A method of developing a procedure for treating a cell proliferation-associated disorder, the method comprising:
- providing a plurality of subjects suffering from a cell proliferation-associated disorder;
- administering to each subject an effective amount of an RRM2 inhibitor;
- administering to each subject an effective amount of a nucleotide or nucleoside analog following administration of the RRM2 inhibitor, each at a unique time point;
- and
- selecting an optimal time point at which the cell proliferation-associated disorder is inhibited to the greatest extent.
Dependencies are inferred from the claim text.